CAS No.25316-40-9,Doxorubicin hydrochloride Suppliers,MSDS download

Products Categories

Pharmaceutical (418)
Organic Chemicals (39)
Others (21)
Reagent (10)
Plant Extract (7)
Materials (3)
Basic Inorganic Chemicals (2)
(1)
Synthetic Flavours & Fragrances (1)

Basic Information

Molecular Structure:
CAS No.:	25316-40-9
Name:	Doxorubicin hydrochloride
Article Data:	13
Cas Database

Formula:	C₂₇H₃₀ClNO₁₁
Molecular Weight:	579.988
Synonyms:	5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S,10S)- (9CI);5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-;Adriamycin, hydrochloride (8CI);ADM hydrochloride;ADR;Adriablastina CS;Adriacin;Adriamycin;Adriblastin;Adriblastina;Adriblastina RD;DOX HCl;FI 106;FI 6804;Lipo-Dox;
EINECS:	246-818-3
Melting Point:	216 °C (dec.)(lit.)
Boiling Point:	810.3 °C at 760 mmHg
Flash Point:	443.8 °C
Solubility:	Soluble in water.
Appearance:	orange-red crystalline solid
Hazard Symbols:	T,T+
Risk Codes:	45-22-40-26/27/28
Safety:	53-45-36/37/39-22-7/9
PSA:	206.07000
LogP:	1.50360

Synthetic route

: 29742-67-4
14-bromodaunorubicin hydrochloride

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
In water; dimethyl sulfoxide at 80℃; for 2h;	64%

: C61H69N7O18*5.7HCl

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;

: C63H70N8O18*7.5HCl

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;

: C69H76N8O20*6.5HCl

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With human protease plasmin In various solvent(s) at 37℃; pH=7.3; Product distribution; Enzymatic reaction;

: 23541-50-6
daunomycin hydrochloride

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: 54 percent / bromine / methanol; dioxane; CHCl3 / 144 h / 0 - 5 °C 2: 64 percent / dimethylsulfoxide; H2O / 2 h / 80 °C View Scheme

doxorubicin hydrochloride: doxorubicin hydrochloride

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
Purification / work up;

: doxorubicin

: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With 3,6-dimethyl-1,2,4,5-tetrazine In acetonitrile Reagent/catalyst;
With 3,6-dimethyl-1,2,4,5-tetrazine In acetonitrile Reagent/catalyst;

: N-((R)-1-((R)-2-(((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl)isonicotinamide

A: N-(pyridin-4-carbonyl)-D-Ala-L-Proline

B: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With fibroblast activating protein In water Kinetics; Reagent/catalyst; Enzymatic reaction;

: C44H42F2N4O14

A: C17H15F2N3O4

B: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
With fibroblast activating protein In water Enzymatic reaction;

: C47H55N5O20S2

A: C21H30N4O10S3

B: 25316-40-9
doxorubicin hydrochloride

Conditions

Conditions	Yield
Stage #1: C47H55N5O20S2 With triethyl ammonium acetate; triethylamine In aq. buffer at 20℃; for 2h; pH=9.5 - 9.9; Darkness; Stage #2: With acetic acid In aq. buffer pH=8.2; Darkness; Stage #3: In aq. buffer pH=6-7; Darkness;

Raw Materials

Downstream Products

Total:266 Page 1 of 7 1 2 3 4 5 6 …7 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 25316-40-9

Consensus Reports

NTP 10th Report on Carcinogens. EPA Genetic Toxicology Program.

Specification

The Doxorubicin hydrochloride, with the CAS registry number 25316-40-9,is also known as (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride. It belongs to the product categories of Pharmaceuticals;Antitumour. This chemical's molecular formula is C₂₇H₂₉NO₁₁^.HCl and molecular weight is 579.99.Its EINECS number is 246-818-3. What's more,Its systematic name is Adriamycin hydrochloride. It is a Orange-Red Crystalline Solid which is Used as an antineoplastic.Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of daunorubicin.

Physical properties about Doxorubicin hydrochloride are:
(1)ACD/LogP: 2.821; (2)# of Rule of 5 Violations: 3; (3)ACD/LogD (pH 5.5): 0.02; (4)ACD/LogD (pH 7.4): 1.12; (5)ACD/BCF (pH 5.5): 1.00; (6)ACD/BCF (pH 7.4): 1.62; (7)ACD/KOC (pH 5.5): 1.29; (8)ACD/KOC (pH 7.4): 16.07; (9)#H bond acceptors: 12; (10)#H bond donors: 7; (11)#Freely Rotating Bonds: 11; (12)Flash Point: 443.8 °C; (13)Enthalpy of Vaporization: 123.51 kJ/mol; (14)Boiling Point: 810.3 °C at 760 mmHg; (15)Vapour Pressure: 9.64E-28 mmHg at 25°C.

You can still convert the following datas into molecular structure:
(1)SMILES:Cl.O=C2c1c(O)c5c(c(O)c1C(=O)c3cccc(OC)c23)C[C@@](O)(C(=O)CO)C[C@@H]5O[C@@H]4O[C@H]([C@@H](O)[C@@H](N)C4)C;
(2)Std. InChI:InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1;
(3)Std. InChIKey:MWWSFMDVAYGXBV-RUELKSSGSA-N.

Safety Information of Doxorubicin hydrochloride:
The Doxorubicin hydrochloride is harmful if swallowed and very toxic by inhalation, in contact with skin and if swallowed. It may cause cancer. But there is limited evidence of a carcinogenic effect. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) .Avoid exposure - obtain special instructions before use. When you use it ,wear suitable protective clothing, gloves and eye/face protection ,and do not breathe dust. After you use it ,keep container tightly closed, and keep container in a well-ventilated place.

The toxicity data of Doxorubicin hydrochloride are as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	LDLo	intravenous	2571ug/kg/3W- (2.571mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Archives of Internal Medicine. Vol. 137, Pg. 385, 1977.
man	TDLo	intravenous	12mg/kg/26W-I (12mg/kg)	CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA	Annals of Internal Medicine. Vol. 106, Pg. 814, 1987.
mouse	LD50	intramuscular	13700ug/kg (13.7mg/kg)		Drugs in Japan Vol. 6, Pg. 506, 1982.
mouse	LD50	intraperitoneal	11160ug/kg (11.16mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	intravenous	1245ug/kg (1.245mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	oral	698mg/kg (698mg/kg)	SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: MUSCLE WEAKNESS	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
mouse	LD50	subcutaneous	7678ug/kg (7.678mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
rabbit	LD50	intravenous	5980ug/kg (5.98mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: FOOD INTAKE (ANIMAL)	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat	LD50	intramuscular	16mg/kg (16mg/kg)		Drugs in Japan Vol. 6, Pg. 506, 1982.
rat	LD50	intraperitoneal	16030ug/kg (16.03mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE"	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat	LD50	intravenous	12510ug/kg (12.51mg/kg)		Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat	LD50	intravenous	12510ug/kg (12.51mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE"	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.
rat	LD50	subcutaneous	21840ug/kg (21.84mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER TOPICAL EXPOSURE" GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1052, 1973.